Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trialGary Middleton, John P. Neoptolemos, William Greenhalf et al.|The Lancet Oncology|2014Cited by 374
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trialGary Middleton, John P. Neoptolemos, Fareeda Y. Coxon et al.|The Lancet Oncology|2017Cited by 73
A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer.Gary Middleton, John P. Neoptolemos, Fareeda Y. Coxon et al.|Journal of Clinical Oncology|2013Cited by 19
A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer.Gary Middleton, John P. Neoptolemos, Fareeda Y. Coxon et al.|Journal of Clinical Oncology|2013Cited by 18
Time From Colorectal Cancer Surgery to Adjuvant ChemotherapyMikail Gögenur, Niels Henrik Holländer, Karen Allan et al.|JAMA Surgery|2024Cited by 14